147 related articles for article (PubMed ID: 37112698)
21. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
[TBL] [Abstract][Full Text] [Related]
22. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
medRxiv; 2021 Aug; ():. PubMed ID: 34462762
[TBL] [Abstract][Full Text] [Related]
23. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.
Achiron A; Mandel M; Dreyer-Alster S; Harari G; Magalashvili D; Sonis P; Dolev M; Menascu S; Flechter S; Falb R; Gurevich M
Ther Adv Neurol Disord; 2021; 14():17562864211012835. PubMed ID: 34035836
[TBL] [Abstract][Full Text] [Related]
24. Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients.
Trümpelmann S; Schulte-Mecklenbeck A; Steinberg OV; Wirth T; Fobker M; Lohmann L; Lünemann JD; Wiendl H; Gross CC; Klotz L
Clin Transl Sci; 2022 Jul; 15(7):1606-1612. PubMed ID: 35213793
[TBL] [Abstract][Full Text] [Related]
25. Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects.
Maniscalco GT; Ferrara AL; Liotti A; Manzo V; Di Battista ME; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Alfieri G; Di Iorio W; Della Rocca G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Jun; 62():103800. PubMed ID: 35462168
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2-specific antibody responses following BNT162b2 vaccination in individuals with multiple sclerosis receiving different disease-modifying treatments.
Lambrianides A; Deeba E; Hadjiagapiou M; Pantzaris M; Krashias G; Christodoulou C
Front Neurol; 2023; 14():1092999. PubMed ID: 36908621
[TBL] [Abstract][Full Text] [Related]
27. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year.
Disanto G; Galante A; Cantu' M; Sacco R; Mele F; Eisler JJ; Keller F; Bernasconi E; Sallusto F; Zecca C; Gobbi C
Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36396447
[TBL] [Abstract][Full Text] [Related]
29. Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
Jeantin L; Abdi B; Soulié C; Sterlin D; Maillart E; Beigneux Y; Hippolyte A; Belin L; Marcelin AG; Pourcher V; Louapre C
J Neurol Neurosurg Psychiatry; 2023 Dec; 95(1):19-28. PubMed ID: 37479463
[TBL] [Abstract][Full Text] [Related]
30. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
Conte WL
Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
[TBL] [Abstract][Full Text] [Related]
31. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine.
Etemadifar M; Sedaghat N; Nouri H; Lotfi N; Chitsaz A; Khorvash R; Zolfaghari H; Ghasemi Movaghar A; Pourabbas M; Salari M
Mult Scler Relat Disord; 2022 Jan; 57():103417. PubMed ID: 34875487
[TBL] [Abstract][Full Text] [Related]
32. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
[TBL] [Abstract][Full Text] [Related]
33. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.
Palomares Cabeza V; Kummer LYL; Wieske L; Hagen RR; Duurland M; Konijn VAL; van Dam KPJ; Stalman EW; van de Sandt CE; Boekel L; Verstegen NJM; Steenhuis M; Rispens T; Tas SW; Wolbink G; Killestein J; Kuijpers TW; van Ham SM; Eftimov F; Brinke AT; van Kempen ZLE;
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35523569
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination.
van Dam KPJ; Hogenboom L; Stalman EW; Kummer LYL; Steenhuis M; Keijser JBD; Brinke AT; van Ham SM; Kuijpers TW; Rispens T; Wieske L; Eftimov F; Strijbis EM; Killestein J; van Kempen ZLE
Front Neurol; 2022; 13():1032830. PubMed ID: 36438945
[TBL] [Abstract][Full Text] [Related]
36. Antibodies against SARS-CoV-2 S and N proteins in relapsing-remitting multiple sclerosis patients treated with disease-modifying therapies.
Kulikowska J; Czarnowska A; Gudowska-Sawczuk M; Kulczyńska-Przybik A; Bazylewicz M; Collins F; Chorąży M; Mroczko B; Kochanowicz J; Kapica-Topczewska K; Kułakowska A
Neurol Neurochir Pol; 2023; 57(1):121-130. PubMed ID: 36421067
[TBL] [Abstract][Full Text] [Related]
37. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
[TBL] [Abstract][Full Text] [Related]
38. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Cohen JA; Bermel RA; Grossman CI; Hersh CM; Hyland M; Mowry EM; Naismith R; Naylor ML; Nicholas J; Rajbhandar R; Singh CM; Tintorè M; Zabalza A; Ziemssen T; Williams JR; Montalban X
Mult Scler; 2022 Jun; 28(7):1131-1137. PubMed ID: 34994577
[TBL] [Abstract][Full Text] [Related]
39. Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs.
Meca-Lallana V; Esparcia-Pinedo L; Aguirre C; Díaz-Pérez C; Gutierrez-Cobos A; Sobrado M; Carabajal E; Río BD; Ropero N; Villagrasa R; Vivancos J; Sanchez-Madrid F; Alfranca A
Clin Immunol Commun; 2023 Dec; 3():6-13. PubMed ID: 38014396
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
